outset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces
Company profile
Ticker
OM
Exchange
Website
CEO
Leslie L. Trigg
Employees
Incorporated
Location
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Fonar ...
Former names
Home Dialysis Plus, Ltd.
SEC CIK
Corporate docs
IRS number
200514392
OM stock data
Latest filings (excl ownership)
8-K
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
13 Mar 24
S-8
Registration of securities for employees
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
8-K
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance
8 Jan 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
2 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Outset Medical Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Outset Medical Reports Preliminary Third Quarter 2023 Financial Results
12 Oct 23
Transcripts
OM
Earnings call transcript
2023 Q3
7 Nov 23
OM
Earnings call transcript
2023 Q3
12 Oct 23
OM
Earnings call transcript
2023 Q2
2 Aug 23
OM
Earnings call transcript
2023 Q2
2 Aug 23
OM
Earnings call transcript
2023 Q1
3 May 23
OM
Earnings call transcript
2022 Q4
13 Feb 23
OM
Earnings call transcript
2022 Q3
9 Nov 22
OM
Earnings call transcript
2022 Q2
5 Aug 22
OM
Earnings call transcript
2022 Q1
5 May 22
OM
Earnings call transcript
2021 Q4
17 Feb 22
Latest ownership filings
4
Marc Nash
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
BRENT D. LANG
13 Mar 24
3
BRENT D. LANG
13 Mar 24
4
Nabeel Ahmed
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Nabeel Ahmed
26 Feb 24
4
Leslie Trigg
26 Feb 24
4
Steven S. Williamson
16 Feb 24
4
Leslie Trigg
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 39.63 mm | 39.63 mm | 39.63 mm | 39.63 mm | 39.63 mm | 39.63 mm |
Cash burn (monthly) | 30.33 k | 4.80 mm | 15.36 mm | 14.60 mm | 11.33 mm | 11.79 mm |
Cash used (since last report) | 180.67 k | 28.57 mm | 91.52 mm | 86.94 mm | 67.50 mm | 70.20 mm |
Cash remaining | 39.45 mm | 11.05 mm | -51.89 mm | -47.32 mm | -27.88 mm | -30.58 mm |
Runway (months of cash) | 1300.4 | 2.3 | -3.4 | -3.2 | -2.5 | -2.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 153 |
Opened positions | 25 |
Closed positions | 26 |
Increased positions | 52 |
Reduced positions | 53 |
13F shares | Current |
---|---|
Total value | 568.07 bn |
Total shares | 53.76 mm |
Total puts | 107.90 k |
Total calls | 22.00 k |
Total put/call ratio | 4.9 |
Largest owners | Shares | Value |
---|---|---|
FMR | 7.47 mm | $81.26 bn |
JPM JPMorgan Chase & Co. | 5.11 mm | $55.55 bn |
Vanguard | 4.77 mm | $51.89 bn |
BLK Blackrock | 3.72 mm | $40.46 bn |
T. Rowe Price Investment Management | 3.17 mm | $34.38 bn |
BLVGF Bellevue | 2.41 mm | $26.20 bn |
Braidwell | 2.40 mm | $26.12 bn |
Champlain Investment Partners | 1.93 mm | $20.96 bn |
AMP Ameriprise Financial | 1.75 mm | $19.04 bn |
MS Morgan Stanley | 1.60 mm | $17.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Marc Nash | Common Stock | Sell | Dispose S | No | No | 2.13 | 2,391 | 5.09 k | 242,510 |
12 Mar 24 | Lang Brent D. | Common Stock | Grant | Acquire A | No | No | 0 | 108,024 | 0.00 | 108,024 |
1 Mar 24 | Nabeel Ahmed | Common Stock | Sell | Dispose S | No | No | 3.15 | 1,584 | 4.99 k | 322,877 |
29 Feb 24 | Nabeel Ahmed | Common Stock | Other | Acquire J | No | No | 2.68 | 1,584 | 4.25 k | 324,461 |
23 Feb 24 | Nabeel Ahmed | Common Stock | Payment of exercise | Dispose F | No | No | 3.72 | 10,639 | 39.58 k | 322,877 |
23 Feb 24 | Nabeel Ahmed | Common Stock | Grant | Acquire A | No | No | 0 | 20,922 | 0.00 | 333,516 |
News
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March
19 Mar 24
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
22 Feb 24
NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday
22 Feb 24
Recap: Outset Medical Q4 Earnings
21 Feb 24
Outset Medical Q4 2023 Adj EPS $(0.59) Beats $(0.61) Estimate, Sales $30.51M Beat $30.40M Estimate
21 Feb 24
Press releases
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
13 Mar 24
ROLLINS, INC. ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
20 Feb 24
Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024
5 Feb 24
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and Non-GAAP Gross Margin Guidance
8 Jan 24
Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
3 Jan 24